TITLE

Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus

AUTHOR(S)
Stolar, Mark W.
PUB. DATE
December 2010
SOURCE
Mayo Clinic Proceedings;Dec2010 Supplement, Vol. 85, pS50
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Traditionally, successful treatment of patients with type 2 diabetes mellitus (DM) has been defined strictly by achievement of targeted glycemic control, primarily using a stepped-care approach that begins with changes in lifestyle combined with oral therapy that is slowly intensified as disease progression advances and β-cell function declines. However, stepped care is often adjusted without regard to the mechanism of hyperglycemia or without long-term objectives. A more comprehensive definition of treatment success in patients with type 2 DM should include slowing or stopping disease progression and optimizing the reduction of all risk factors associated with microvascular and macrovascular disease complications. To achieve these broader goals, it is important to diagnose diabetes earlier in the disease course and to consider use of more aggressive combination therapy much earlier with agents that have the potential to slow or halt the progressive β-cell dysfunction and loss characteristic of type 2 DM. A new paradigm for managing patients with type 2 DM should address the concomitant risk factors and morbidities of obesity, hypertension, and dyslipidemia with equal or occasionally even greater aggressiveness than for hyperglycemia. The use of antidiabetes agents that may favorably address cardiovascular risk factors should be considered more strongly in treatment algorithms, although no pharmacological therapy is likely to be ultimately successful without concomitant synergistic lifestyle changes. Newer incretin-based therapies, such as glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, which appear to have a favorable cardiovascular safety profile as well as the mechanistic possibility for a favorable cardiovascular risk impact, are suitable for earlier inclusion as part of combination regimens aimed at achieving comprehensive treatment success in patients with type 2 DM.
ACCESSION #
60684524

 

Related Articles

  • Alpha cell function in health and disease: influence of glucagon-like peptide-1. Dunning, B. E.; Foley, J. E.; Ahrén, B. // Diabetologia;Sep2005, Vol. 48 Issue 9, p1700 

    Although there is abundant evidence that hyperglucagonaemia plays a key role in the development of hyperglycaemia in type 2 diabetes, efforts to understand and correct this abnormality have been overshadowed by the emphasis on insulin secretion and action. However, recognition that the incretin...

  • The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Wiernsperger, N.F.; Bailey, C.J. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p31 

    Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose concentrations in type 2 (non-insulin-dependent) diabetes without causing overt hypoglycaemia. Its clinical efficacy requires the presence of insulin and involves several therapeutic effects. Of these effects,...

  • CLINICAL CLIPS / EVIDENCE-BASED MEDICINE. Russell, John J.; Beck, Jonathan D.; Paist, S. Scott; Chambers, Christopher V.; Kirchner, Jeff; Pohl, Charles A. // Patient Care for the Nurse Practitioner;Dec2005, Vol. 8 Issue 12, p6 

    The article talks about a study on inhaled insulin in type 2 diabetes. The trial of 309 patients with type 2 diabetes and failure of dual oral therapy evaluated the effect on glycemic control of inhaled insulin alone or added to dual oral therapy. Insulin has a rapid onset and patients were...

  • Awareness on Type II Diabetes and Its Complication among Sivaganga District Population in Tamilnadu: A Cross Section Survey. Kasinathan, Devi; Girijakumari, Nisha Rajagopalan; Marimuthu, Prabhu Narayanan; Ramar, Manikandan; Muthusamy, Karthikeyan // Journal of Advanced Scientific Research;Feb2013, Vol. 4 Issue 1, p38 

    Diabetes and its associated complication have been increasing dramatically worldwide. Prevalence of diabetes is higher in developed than in developing countries, however past two decades diabetes mellitus was reported higher in developing countries. Diabetes and its associated complication...

  • SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory. Paneni, Francesco; Volpe, Massimo; Lüscher, Thomas Felix; Cosentino, Francesco // Diabetes;Jun2013, Vol. 62 Issue 6, p1800 

    The article discusses a study which investigated the persistence of hyperglycemic stress despite glucose normalization, which has been called hyperglycemic memory. It is noted that the emerging concept confirms the importance of early glycemic control and explains the persistence of diabetic...

  • Hyperosmolar Hyperglycemic State: A Historic Review of the Clinical Presentation, Diagnosis, and Treatment. Pasquel, Francisco J.; Umpierrez, Guillermo E. // Diabetes Care;Nov2014, Vol. 37 Issue 11, p3124 

    The hyperosmolar hyperglycemic state (HHS) is the most serious acute hyperglycemic emergency in patients with type 2 diabetes. von Frerichs and Dreschfeld described the first cases of HHS in the 1880s in patients with an "unusual diabetic coma" characterized by severe hyperglycemia and...

  • Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Ye-Fong Du; Horng-Yih Ou; Beverly, Elizabeth A; Ching-Ju Chiu // Clinical Interventions in Aging;2014, Vol. 9, p1963 

    The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the elderly. Because of the unique characteristics of elderly people with T2DM, therapeutic strategy and focus should be tailored to suit this population. This article reviews the guidelines and studies related to older people...

  • Oolong Tea: An Adjunct To Antidiabetic Drugs?  // RN;Nov2003, Vol. 66 Issue 11, p23 

    Reports on research on the antihyperglycemic effect of oolong tea in type 2 diabetes. Plasma glucose levels in patients after a 30-day period.

  • New insulin analog provides mealtime glucose control. LoBuono, Charlotte // Drug Topics;5/17/2004, Vol. 148 Issue 10, p28 

    This article reports that clinicians will soon be able to offer their patients with Type 1 and Type 2 diabetes a rapid-acting human insulin analog designed to cover mealtime spikes in blood glucose levels. The U.S. Food and Drug Administration recently approved the insulin glulisine for the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics